source
- Merck and Moderna report Phase 3 success for personalized mRNA cancer vaccine intismeran autogeneMerck and Moderna announced on August 19, 2026 that their personalized mRNA cancer vaccine, intismeran autogene, has completed a successful Phase 3 trial. The collaboration aims to create a patient…
- Moderna cancer vaccine data lifts investor confidence, shares jump to multi-year highsModerna has long said it wants to broaden its portfolio beyond infectious-disease vaccines. The company has been working on a cancer vaccine and investors have been waiting for late-stage trial res…